Feb. 8, 2013
/PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that
Gerald E. Commissiong
, President and Chief Executive Officer will present a corporate update at the 15
& Investor Conference hosted by the Biotechnology Industry Organization (BIO). The presentation will take place on
Monday, February 11, 2013
at the Waldorf Astoria in
New York, NY
The presentation will be webcast and available in the IR Calendar section of the Company's website at
About Amarantus BioScience, Inc.
Amarantus BioScience, Inc. is a development-stage biotechnology company founded in
. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property and licenses for the diagnosis of Parkinson's disease and Alzheimer's disease. For further information please visit
Amarantus Bioscience, Inc.
IR Sense, LLC
(408) 737-2734 x109
SOURCE Amarantus BioScience, Inc.